Human intestinal organoid screening platform for drug discovery
Official title: A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing
Funded at Intero Biosystems INC. · NIH-11408237 · Data updated 2026-11-12
A patient-friendly project that aims to create advanced human intestinal models to better predict how drugs will behave in people.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intero Biosystems INC. NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | July 1, 2026 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,046,897 |
| NIH project number | 2R44TR005379-02 |
| Project ID | NIH-11408237 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with gastrointestinal conditions or researchers wanting better preclinical drug testing models that reflect human biology.
✕Less likely to help
Patients without interest in drug development or preclinical testing methods may not directly benefit.
What this research studies
This project uses stem cell–derived intestinal organoids that mimic real human tissue to test drugs. It focuses on making scalable, high-throughput assays that can identify toxic effects and antifibrotic benefits in the gut. The work will standardize quality control, storage, and distribution so researchers and companies can reliably use the models. By simulating normal and diseased intestinal conditions, it aims to improve safety and efficacy predictions before human trials.
Why it matters
Potential benefit: If successful, this platform could reduce late-stage drug failures and speed safer therapies to patients.
How similar studies have gone: Previous organoid-based approaches show promise but this project emphasizes scalable, industry-ready assays and quality benchmarks.
Where this research is happening
-
Intero Biosystems INC.
Aurora, United States Active
Researchers
- Principal investigator: Childs, Charlie — Intero Biosystems INC.
- Study coordinator: Childs, Charlie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.